Assembly Biosciences, Inc. Cash and Restricted Cash
Assembly Biosciences, Inc. (ASMB) had Cash and Restricted Cash of $34.26 million as of 2019-06-30, per its 10-Q filed 2019-08-05.
Discontinued › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2019-08-05
- 2019-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $34.26M.
- 2018-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $41.47M.
- 2018-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $54.19M.
- 2017-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $82.03M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2019-06-30 | $34.26M 10-Q · filed 2019-08-05 |
| 2018-12-31 | $41.47M 10-Q · filed 2019-08-05 |
| 2018-06-30 | $54.19M 10-Q · filed 2019-08-05 |
| 2017-12-31 | $82.03M 10-Q · filed 2019-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |